STENTYS Event | Date * |
Q4 Full Year Sales 2015 | Wednesday, January 13, 2016 |
Full-Year Results 2015 | Wednesday, March 16, 2016 |
Q1 Sales 2016 | Wednesday, April 13, 2016 |
Shareholders' General Meeting | Wednesday, May 11, 2016 |
Q2 Sales 2016 | Tuesday, July 12, 2016 |
Half-Year Results 2016 | Thursday, September 15, 2016 |
Q3 Sales 2016 | Wednesday, October 12, 2016 |
Financial year ended 31 December
* Subject to modification. Press releases are distributed after the financial markets closure.
STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex coronary artery disease. STENTYS' Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company's product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS' commercial network in Europe, the Middle East, Asia and Latin America. More information is available at www.stentys.com.
STENTYS Stanislas Piot CFO Tel.: +33 (0)1 44 53 99 42 stan.p@stentys.com | NewCap Investor Relations / Strategic Communications Dusan Oresansky Tel.: +33 (0)1 44 71 94 93 stentys@newcap.fr | LifeSci Advisors LLC Andrew McDonald Tel: +1.646.597.6987 andrew@lifesciadvisors.com |
STENTYS is listed on Comp. C of the Euronext Paris ISIN: FR0010949404 - Ticker: STNT | ||
Page 1 of 1
Stentys SA issued this content on 2015-12-22 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2015-12-22 17:02:21 UTC
Original Document: http://www.stentys.com/file_bdd/documents/1450804247_Stentys_Agenda2016_ENG.pdf
